Vaccination to prevent herpes zoster and postherpetic neuralgia

Human Vaccines

Volumn 3, Issue 2, 2007, Pages 64-68

  Oxman, Michael N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adult vaccination; Burden of Illness; Herpes Zoster; Pain; Postherpetic neuralgia; Prevention; Shingles; Shingles Prevention Study; Varicella zoster virus; ZOSTAVAX

Indexed keywords

VARICELLA ZOSTER VACCINE;

ANTIVIRAL THERAPY; CELLULAR IMMUNITY; CHICKENPOX; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DERMATOME; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; HERPES ZOSTER; HUMAN; IMMUNOCOMPETENCE; INCIDENCE; INJECTION SITE PAIN; NOTE; POSTHERPETIC NEURALGIA; QUALITY OF LIFE; RADICULAR PAIN; SENSORY NERVE CELL; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 33947678686     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.2.3746     Document Type: Note

References (36)

1. Gnann JW Jr, Whitley RJ. Herpes zoster. N Engl J Med 2002; 347:340-6.
2. Oxman MN. Clinical manifestations of herpes zoster. In: Arvin AM and Gershon AA, eds. Varicella zoster virus: Virology and clinical management. Cambridge, UK: Cambridge University Press, 2000: 246-75.
3. Hope-Simpson RE. The nature of herpes zoster: A long term study and a new hypothesis. Proc R Soc Med 1965; 58:9-20.
4. Head H, Campbell AW. The pathology of herpes zoster and its bearing on sensory localization. Brain 1900; 23:353-523.
5. Denny-Brown D, Adams RD, Fitzgerald PJ. Pathologic features of herpes zoster: a note on "geniculate herpes". Arch Neurol Psychiatr 1944; 51:216-31.
6. Weller TH. Varicella and herpes zoster: changing concepts of the natural history, control, and importance of a not so benign virus. N Engl J Med 1983; 309:1434-40.
7. Ragozzino MW, Melton LF III, Kurland LT. Population-based study of herpes zoster and its sequelae. Medicine 1982;61:310-6.
8. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155:1605-9.
9. Kost RG, Sttaus SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med 1996; 335:32-42.
10. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996; 67:241-51.
11. Schmader K. Herpes zoster in older adults. Clin Infect Dis 2002; 32:1481-6.
12. Miller AE. Selective decline in cellular immune response to varicella zoster in the elderly. Neurology 1980; 30:582-7.
13. Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun 1981; 32:24-27.
14. Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune rvaricella-zosteresponse to varicella-zoster in the aged. Arch Intern Med 1982; 142:291-3.
15. Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, Shaw A, Silber JL, Schlienger K, Chalikonda I, Vessey SJ, Caulfield MJ. Decline in varicella-zoster virus (VZV) specific cell mediated immunity with increasing age and boosting with a high dose VZV vaccine. J Infect Dis 2003; 188:1336-44.
16. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simbetkoff MS, Gershon AA, Davis LE, et al. Prevention of Herpes Zoster and Postherpetic Neuralgia in Older Adults With A Live Attenuated Varicella-Zoster Virus Vaccine: Results of Department of Veterans Affairs Cooperative Study #403 - The Shingles Prevention Study. N Engl J Med 2005; 352:2271-84.
17. Hope-Simpson RE. Postherpetic neuralgia. J Roy Coll Gen Pract 1975; 25:571-5.
18. Galil K, Choo PW, Donahue JG, Platt R. The sequelae of herpes zoster. Arch Intern Med 1997; 157:1209-13.
19. Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995; 45, Suppl 8:S52-3.
20. Dworkin RH, Schmader KE. The treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003; 36:877-82.
21. Oxman MN: Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995; 45 [Suppl]:41-6.
22. Levin MJ, Murray M, Rorbarr HA, Zerbe GO, White J, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992; 166:253-9.
23. Dolin R, Reichman RC, Mazur MH, Whitley RJ. NIH conference: herpes zoster-varicella infections in immunosuppressed patients. Ann Intern Med 1978; 89:375-88.
24. Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella zoster viral antigens after bone marrow Transplantation. J Infect Dis 1992; 165:119-26.
25. Buchbinder SP, Katz MH, Hessol NA, Liu JY, O'Malley PM, Underwood R, Holmberg SD. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992; 166:1153-6.
26. Ljungman P, Lonnqvist B, Gahrron G, Ringden O, Sundqvist VA, Wahren B. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis 1986; 153:840-7.
27. Berger R, Luescher D, Just M. Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. J Infect Dis 1984; 149:647.
28. Berger R, Amstuct I, Just M, Just V, Luescher D. Booster vaccination of healthy adults with VZV antibody but without a VZV specific cell mediated immune response. Antiviral Res 1985; 1(suppl 1):267-71.
29. Takahashi M, Ikerani T, Sasada K, Hara J, Kamiya H, Asano Y, Baba K, Shiraki K. Immunization of the elderly and patients with collagen vascular diseases with live varicella vaccine and use of varicella skin antigen. J Infect Dis 1992; 166:58-62.
30. Levin MJ, Barbet D, Goldblatt E, Jones M, LaFleur B, Chan C, Stinson D, Zerbe GO, Hayward AR. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998; 178:S109-12.
31. Trannoy E, Berger R, Hollander G, Bailleux F, Heimendinger P, Vuillier D1 Creusvaux H. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000; 18:1700-6.
32. Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventoty. J Pain 2004; 5:344-56.
33. Oxman M, Levin M, Johnson G, Zhang J, Caulfield M, Shingles Prevention Study Group, The Effect of Age on Clinical and Immunologie Responses to a Herpes Zoster Vaccine, Abstract # 858, Program and Abstracts, 44th Annual Meeting of the Infectious Diseases Society of America, Toronto, October 12 15, 2006; 191-2.
34. Oxman, MN. Results of the Shingles Prevention Study, Presentation to the ACIP, Atlanta, 25 October 2006.
35. Messonnier ML, Zhou F, Review of Economic Studies of Varicella Zoster Vaccine. Presentation to the ACIP, Atlanta, 25 October 2006.
36. Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, Arvin AMI. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Eng J Med 2002; 347:26-34.